Vishnu Patel, MD
Pulmonary Disease · Princeton, WVNPI 1265400865
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 523 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AstraZeneca at 28.9% of the total. 2025 is the largest year on record at $2,604, 3.3 times the $793 reported in 2019.
Across 523 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Boehringer Ingelheim$1K
- Jazz Pharmaceuticals Inc.$475
- Takeda Pharmaceuticals U.S.A., Inc.$464
- Axsome Therapeutics, Inc.$360
- plus $3K from 29 others
What the payments were for
- Food & beverage$10,06299%
- Education$1531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 139 | $2,951 |
| GSK | 123 | $1,808 |
| Boehringer Ingelheim | 58 | $1,039 |
| Jazz Pharmaceuticals Inc. | 18 | $475 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $464 |
| Axsome Therapeutics, Inc. | 18 | $360 |
| Baxter Healthcare | 14 | $325 |
| Pulmonx Corporation | 15 | $322 |
| Mylan Specialty L.p. | 16 | $299 |
| Amgen | 12 | $242 |
| Regeneron Healthcare Solutions, Inc. | 12 | $207 |
| AbbVie(2 entities) | 7 | $165 |
| Inspire Medical Systems, Inc. | 2 | $163 |
| United Therapeutics Corporation | 1 | $157 |
| Sanofi | 7 | $156 |
| Teva Pharmaceuticals USA, Inc. | 6 | $115 |
| Philips North America LLC | 6 | $111 |
| Verona Pharma, Inc. | 5 | $108 |
| Harmony Biosciences LLC | 5 | $101 |
| Sunovion Pharmaceuticals Inc. | 5 | $94 |
| Grifols USA, LLC | 3 | $72 |
| Viatris Specialty LLC | 3 | $64 |
| Insmed, Inc. | 3 | $61 |
| Actelion Pharmaceuticals US, Inc. | 1 | $59 |
| CSL Behring | 2 | $52 |
| Shire North American Group Inc | 3 | $50 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $40 |
| Merck | 2 | $33 |
| Apria Healthcare LLC | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Inogen, Inc. | 2 | $15 |
| Electromed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,215 in reported general payments places this provider in the 85th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,178 | $872,664 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 322 | $239,906 |
| Breo ElliptaFluticasone/Vilanterol | 409 | $195,253 |
| OfevNintedanib Esylate | 13 | $168,864 |
| SymbicortBudesonide/Formoterol Fumarate | 514 | $144,268 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 133 | $84,862 |
| Fasenra PenBenralizumab | 14 | $79,475 |
| Spiriva RespimatTiotropium Bromide | 128 | $67,030 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,822 | $62,981 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 117 | $61,790 |
| Spiriva HandihalerTiotropium Bromide | 94 | $56,975 |
| TezspireTezepelumab-Ekko | 13 | $51,052 |
| Advair HfaFluticasone Propion/Salmeterol | 123 | $46,956 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 203 | $41,151 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 246 | $37,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,808 | $1,178,3011,848 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Tezspire, Bevespi Aerosphere | $2,951 | $444,585864 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,039 | $333,728297 claims |
| PfizerEliquis | $17 | $17,01328 claims |
| MerckDulera | $33 | $8,06525 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $115 | $4,22314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Princeton
- Melvin SaludesGlen Dale$255K
- Roger AbrahamsMorgantown$133K
- Maria BoustaniBeckley$95K
- Ramzi HaddadinBeckley$43K
- Salam RajjoubBridgeport$29K
- Peter KochupuraMorgantown$22K
- Phillip AguilaMartinsburg$21K
- Ryan WaddellCharleston$13K
- Loay Al AsadiCharleston$13K
- Houssein YounessMartinsburg$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.